Why India rejected a patent application for shorter drug-resistant TB treatment | Explained
India rejects TB drug breakthrough patent, potentially boosting generic competition and access to a shorter all-oral BPaL regimen for drug-resistant TB.
The Hindu asks for a subscription to read the full story. If you have one, sign in on their site.
0 comments